πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

140 results for β€œcar-t” Clear

  1. anti-BCMA CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Plasma Cell Leukemia

    phase 2 mab active

    1 trial

  2. anti-BCMA-CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 mab active

    2 trials

  3. anti-FLT3 CAR-T

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  4. 19(T2)28z1xx CAR T cells

    Takeda

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule active

    1 trial

  5. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

  6. A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial

    The George Institute

    Locally advanced, recurrent, or metastatic breast, gastric, endometrial, and selected other solid tumors with positive expression for HER-2 (3+)

    phase 1 other active

    1 trial

  7. ADCLEC.syn1 CAR T cells

    Takeda

    Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  8. ATHENA CAR-T

    The First People's Hospital of Lianyungang

    Lupus Erythematosus, Systemic

    phase 1 mab active

    1 trial

  9. Allogeneic CD19/BCMA-targeted CAR-Ξ³Ξ΄T cell injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory/Relapsed Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  10. Allogeneic anti-CD7 CAR-T cells (BEAM-201)

    Beam Therapeutics

    T-Cell Acute Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  11. Anti-BCMA CAR-T cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  12. Anti-CD19 UCAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Dermatomyositis, Juvenile

    phase 1 small molecule active

    1 trial

  13. Anti-CD19 Universal CAR-T Cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  14. Anti-CD30 CAR T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Adult T-Cell Lymphoma/Leukaemia

    phase 1 gene therapy active

    1 trial

  15. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  16. Arm 1: IL13Ra2-specific CAR Tcm cells

    BRIGHT MINDS BIOSCIENCES INC.

    Recurrent Glioblastoma

    phase 1 mab active

    1 trial

  17. BCMA/CD19 Dual-Target CAR-T

    Xijing Hospital

    Multiple Myeloma

    phase 1 mab active

    1 trial

  18. BCMA/CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  19. BCMA/CD70-targetd CAR-T

    Chongqing Precision Biotech Co., Ltd

    Juvenile Dermatomyositis (JDM)

    phase 1 mab active

    1 trial

  20. CAR T cells

    Qian Wenbin

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  21. CAR T cells chimeric antigenreceptor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  22. CAR T-cell therapy

    Hospital Authority, Hong Kong

    Lymphoblastic Leukemia, Acute, Childhood

    phase 1 mab active

    1 trial

  23. CAR-T

    The Third Affiliated Hospital of Southern Medical University

    Multiple Myeloma

    phase 1 mab active

    1 trial

  24. CAR-T Re-treatment

    Nanjing Legend Biotech Co.

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources